Browse our Medical Journals

Among all scientific traditions alive, medical publishing has a good chance to be the oldest. The first fully peer reviewed academic journal, “Medical Essays and Observations” was launched in 1731 by the Royal Society in Edinburgh. Since then, hundreds of medical journals have been published worldwide. Medical publication in Hungary started in 1857 when the famous physician, Markusovszky founded “Orvosi Hetilap”, which has been published since then every week (with short breaks during the world wars). It is now a most prestigious piece in AKJournals’ portfolio, listed in Journal Citation Reports, with a remarkable impact factor.

Discover the latest journals in Medical and Health Sciences

The primary function of medical articles is the validation of cutting-edge theoretical and clinical research, by providing reference and relevant forums. New drugs and medical practices can only enter the mainstream practise if their randomised trials had passed under the critical lens of prestigious peer reviewed journals. Technical reports help practitioners to improve their arsenal. Case reports confirm theories and provide tools for investigating or disclosing possible malpractice. Review articles serve educational purposes. Some more popular articles may play a role in educating the interested audience.

Types of medical articles

The papers published in medical journals can be classified in the following main categories

  • Research articles report about novel research results, of both theoretical and (direct or indirect) practical relevance.
  • Review articles survey specific topics by summarising and analysing all information available in the medical literature. Reviews are kind of combining results from different studies on the same topic. They can be useful for specialists in the field, may help them to prevent, diagnose, or treat a particular disease.
  • Case reports and case series reports about a concrete story of a concrete patient. They can be interesting because of their uniqueness, not matching any known diagnosis or describing unexpected symptoms. The report should describe each of the diagnosis, treatment, the patient’s response to it and the follow-up history. Case series are related reports about similarly treated patients.
  • Editorials are typically not peer reviewed shorter communications from senior members of the Editorial Board or from invited renown scholars. They discuss questions of relevance for the scientific community at the moment (say, about public health, or more generally, the health system).
  • Letters to the editor are articles of the interactive type, a form for readers to contact the medical journal. They can express comments, questions, or criticisms regarding some articles published in that journal. They provide a sophisticated forum for medical communities.

Medical Journals at AKJournals

AKJournals has 9 medical journals. Three of them are in Hungarian. The other six journals are in English and accept submissions from all over the world. Some of them are widely available Open Access journals. The covered topics include immunology, medical imaging, physiology, and veterinary and health care science. In these journals, you can find more than 11.000 medical articles altogether. A filter tool helps to single out the relevant titles. In addition to that, we highly recommend using the search box to find the most important topics only

Medical and Health Sciences

You are looking at 1 - 10 of 11,140 items for

  • All content x
Clear All


Based on the current literature, the link between Achilles tendon moment arm length and running economy is not well understood. Therefore, the aim of this study was to further investigate the connection between Achilles tendon moment arm and running economy and the influence of Achilles tendon moment arm on the function of the plantarflexor muscle-tendon unit during running.

Ten male competitive marathon runners volunteered for this study. The participants ran on a treadmill at two running speeds: 3 and 3.5 m s−1. During running the oxygen consumption, lower leg kinematics, electrical activity of plantar flexor muscles, and fascicle behavior of the lateral gastrocnemius were measured simultaneously. On the second occasion, an MRI scan of the right leg was taken and used to estimate the Achilles tendon moment arm length.

There was a negative correlation between running economy and the body height normalized moment arm length at both selected speeds (r = −0.68, P = 0.014 and r = −0.70, P = 0.01). In addition, Achilles tendon moment arm length correlated with the amplitude of the ankle flexion at both speeds (r = −0.59, P = 0.03 and r = −0.60, P = 0.03) and with the electrical activity of the medial gastrocnemius muscle at 3 m s−1 speed (r = −0.62, P = 0.02). Our finding supports the concept that a longer moment arm could be beneficial for distance runners.

Open access


In this study, the ability of microRNA-1906 (miR-1906) to attenuate bone loss in osteoporosis was evaluated by measuring the effects of a miR-1906 mimic and inhibitor on the cellular toxicity and cell viability of MC3T3‐E1 cells. Bone marrow-derived macrophage (BMM) cells were isolated from female mice, and tartrate-resistant acid phosphatase signalling was performed in miR-1906 mimic-treated, receptor-activated nuclear factor kappa-B (NF-κB) ligand (RANKL)-induced osteoclasts. In-vivo, osteoporosis was induced by ovariectomy (OVX). Rats were treated with 500 nmol/kg of the miR-1906 mimic via intrathecal administration for 10 consecutive days following surgery. The effect of the miR-1906 mimic on bone mineral density (BMD) in OVX rats was observed in the whole body, lumbar vertebrae and femur. Levels of biochemical parameters and cytokines in the serum of miR-1906 mimic-treated OVX rats were analysed. The mRNA expression of toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), p-38 and NF-κB in tibias of osteoporotic rats (induced by ovariectomy) was observed using quantitative reverse-transcription polymerase chain reaction. Treatment with the miR-1906 mimic reduced cellular toxicity and enhanced the cell viability of MC3T3‐E1 cells. Furthermore, osteoclastogenesis in miR-1906 mimic-treated, RANKL-induced osteoclast cells was reduced, whereas the BMD in the miR-1906 mimic-treated group was higher than in the OVX group of rats. Treatment with the miR-1906 mimic also increased levels of biochemical parameters and cytokines in the serum of ovariectomised rats. Finally, mRNA expression levels of TLR4, MyD88, p-38 and NF-κB were lower in the tibias of miR-1906 mimic-treated rats than in those of OVX rats. In conclusion, the miR-1906 mimic reduces bone loss in rats with ovariectomy-induced osteoporosis by regulating the TLR4/MyD88/NF‐κB pathway.

Restricted access

Összefoglaló. Az akut promyelocytás leukémia (APL) ritka, de jól gyógyítható leukémiatípus. Az APL-es betegek gondozását centralizáltan, az APL kezelésében jártas kórházakban kell végezni, ahol elérhető hematológiai intenzív ellátás. Az APL terápiája az elmúlt két évtizedben rohamosan fejlődött az igen aktív hatású gyógyszerek, a tretinoin és az arzén-trioxid bevezetésével. Immáron a hagyományos citotoxikus kemoterápia alkalmazása nélkül kezelhető a betegség. A legújabb klinikai irányelvek többféle kezelési stratégiát tartalmaznak, ezek egy része továbbra is alkalmazza a citotoxikus kemoterápiát. Ily módon számos kezelési lehetőség áll a gyakorló hematológus rendelkezésére, amikor egy új APL-es beteg ellátását tervezi. Az elmúlt három évtized multicentrikus vizsgálatai igazolták az ATRA + kemoterápia, majd később a kemoterápiával vagy anélkül adott ATRA + ATO alkalmazásának hatásosságát. Az APL optimális kezeléséhez azonban a diagnózis korai felállítása, az agresszív szupportív beavatkozások bevezetése, a kezeléssel összefüggő szövődmények megfelelő rendezése és a mérhető reziduális betegség (az MRD) monitorozása is hozzátartozik. A szerzők az akut promyelocytás leukémia legújabb kezelési irányelveit foglalják össze.

Summary. Acute promyelocytic leukemia (APL) is an uncommon but highly curable leukemia. Treatment of APL patients should be centralised in hospitals with proven experience in APL treatment and haematological intensive care. The treatment of acute promyelocytic leukemia (APL) has evolved rapidly in the past two decades after the introduction of highly active drugs, including tretinoin (all-trans-retinoic acid) and arsenic trioxide. It is now possible to treat this disease without the use of traditional cytotoxic chemotherapy. Today’s clinical guidelines include multiple regimens, some of which continue to use cytotoxic chemotherapy. This leaves the practicing oncologist with multiple treatment options when faced with a new case of APL. Multicenter studies over the past three decades have demonstrated the efficacy of ATRA plus chemotherapy and, subsequently, of ATRA plus ATO, with or without chemotherapy. However, the optimal management of APL also requires early diagnosis, institution of aggressive supportive measures, appropriate management of treatment-related complications and monitoring of measurable residual disease (MRD). The authors summarizes the updated guidelines in the management of acute promyelocytic leukemia.

Open access
Restricted access

Összefoglaló. A mély molekuláris remisszióban lévő CML-es betegnél láz, izomfájdalmak alakultak ki, melyet jelentős kétvonalas cytopenia kísért. Alapbetegségének blasztos transzfomációja mellett, az utazási anamnézisre tekintettel a differenciáldiagnosztika trópusi betegségekre is kiterjedt. Dengue-lázat diagnosztizáltunk, melyből a beteg szövődmény nélkül felépült.

Summary. A CML patient in deep molecular remission was admitted with fever, muscle pain, followed by pronounced bilineage cytopenia. In addition to possible blastic transformation, tropical diseases were also included in the differential diagnosis, due to travel history. Dengue fever was diagnosed, and the patient recovered without any complications.

Restricted access
Authors: Apor Hardi, András Kozma, Andrea Ceglédi, Ágnes Tomán, András Bors, Hajnalka Andrikovics, and Gábor Mikala

Összefoglaló. A monoklonális ellenanyagokat termelő plazmasejtburjánzás, a myeloma multiplex kezelésére a monoklonális ellenanyag-terápia viszonylag későn lépett a klinikumba. 2020 végén már három törzskönyvezett antitest, az elotuzumab, a daratumumab és az isatuximab áll rendelkezésre különböző gyógyszer-kombinációk részeként a myeloma betegség eltérő terápiás helyzeteinek megoldására. Emellett számos új antitest, nemcsak „csupasz” antitestek, hanem antitestdrug konjugátumok és bispecifikus antitestek állnak viszonylag előrehaladott klinikai fejlesztési stádiumban, közvetlenül a bevezetés előtt. Összefoglalónkban a rendelkezésünkre álló nagyszámú tanulmány eredményeit ismertetjük, fogódzót kínálva a terület eredményeit kritikus szemmel megismerni kívánó olvasóknak.

Summary. Although multiple myeloma is a plasma cell malignancy known to produce monoclonal antibodies, therapeutic monoclonal antibodies entered late into this clinical field. At the end of 2020, we already have three approved monoclonal antibodies: elotuzumab, daratumamab, and isatuximab – available in different drug combinations at different therapeutic settings of multiple myeloma. Additionally, there are a number of new antibodies, not just „bare” antibodies but antibody-dug conjugates and bispecific antibodies stand at advanced stages of clinical development, frequently just before approval. In this review, results of the large number of clinical studies are critically detailed in order to provide assistance for our interested readers.

Restricted access
Authors: László Szerafin, Péter Takács, Gabriella Varjasi, László Rejtő, Péter Ilonczai, Lóránt Varju, Katalin Keresztes, and János Jakó

Összefoglaló. Bevezetés: A krónikus lymphoid leukémia kezelésében jelentős előrelépést eredményezett az ibrutinibterápia bevezetése. A gyógyszer első vonalbeli és többed vonalbeli kezelése is magas remissziós arányt eredményezett, bár a terápia korai bevezetése és a kedvező genetikai eltérések esetén az eredmények jobbak. A progressziómentes túlélést befolyásoló egyéb tényezőkről azonban még kevés adat áll rendelkezésre. Célkitűzés: Krónikus lymphoid leukémiás betegek ibrutinibkezelése során a teljes hematológiai remisszió elérését és a progressziómentes túlélés időtartamát befolyásoló tényezők vizsgálata. Betegek és módszer: 47 krónikus lymphoid leukémiás beteg (életkor: 39–84 év, férfi 27, nő 20, követési idő 5–58 hónap, medián 15 hónap) klinikai és laboratóriumi adatainak retrospektív elemzése. Eredmények: A teljes hematológiai remisszió elérése független volt a betegek nemétől, életkorától, a betegség stádiumától, az immunglobulin gén nehézlánc-variábilis régió státuszától, a genetikai aberrációktól, az abszolút neutrophilszámtól, az abszolút monocytaszámtól és a vörösvértestnagyság-eloszlási görbe szélességétől. A progressziómentes túlélést a komplett remisszió elérése (p = 0,00073) és a magasabb abszolút neutrophilszám (<4 G/l vs. ≥4 G/l, p = 0,022) befolyásolta szignifikánsan, a vörösvértestnagyság-eloszlási görbe szélességértékével való összefüggés pedig statisztikailag határértéken volt (p = 0,065). A Cox-féle regressziós elemzésbe bevont változók közül csak a teljes hematológiai remisszió elérése mutatott szignifikáns hatást a progressziómentes túlélésre (p = 0,0147). Következtetések: A teljes hematológiai remisszió elérése az egyéb vizsgált tényezőktől független, szignifikáns hatással bír a betegek progressziómentes túlélésére. Az abszolút neutrophilszám és a vörösvértestnagyság-eloszlási görbe szélessége szintén hasznos kiegészítő prognosztikus marker lehet. Az elemzett esetek száma még alacsony a komolyabb következtetések levonására, azonban így is elmondható, hogy az eredmények egy része már a szakirodalom korábbi eredményeit tükrözi.

Summary. Introduction: The introduction of ibrutinib therapy has led to significant advances in the treatment of chronic lymphocytic leukemia. Both first-line and multiple-lines treatments of the drug resulted in high remission rates, although results were better with early initiation of therapy and favorable genetic abnormalities. However, little data are available on other factors influencing progression-free survival. Objective: To investigate factors influencing the achievement of complete hematological remission and progression-free survival with ibrutinib treatment in patients with chronic lymphocytic leukemia. Patients and metods: Retrospective analysis of clinical and laboratory data from 47 chronic lymphoid leukemia patients (age: 39–84 years, male 27, female 20, follow-up 5–58 months, median 15 months). Results: Achieving complete hematologic remission was independent of patient gender, age, disease stage, immunoglobulin heavy chain variable region status, genetic aberrations, absolute neutrophil count, absolute monocyte count, and red blood cell distribution width. Progression-free survival was significantly affected by complete remission (p = 0.00073), and higher absolute neutrophil counts (<4 G/l vs. ≥ 4 G/l, p = 0.022), the red blood cell distribution width was statistically less significant (p = 0.065). Of the variables included in the Cox regression analysis, only the achievement of complete hematologic remission had a significant effect on progression-free survival (p = 0.0147). Conclusions: Achieving complete hematologic remission, independent of the other factors studied, has a significant effect on patients’ progression-free survival. Absolute neutrophil count and red blood cell distribution width can also be a useful additional prognostic marker. The number of analyzed cases is still low to draw more serious conclusions, but it can still be said that some of the results already reflect previous results in the literature.

Open access


This study was to investigate whether high-intensity interval training (HIIT) and saffron aqueous extract (SAE) would provide a synergistic effect to improve tumor volume reduction and also modulate pro- and anti-apoptotic protein expression in tumor tissue of 4T1 breast cancer-bearing mice. Female mice following induction of breast cancer through injection of 4T1 cell lines were randomly divided into four groups: (1) HIIT, (2) SAE, (3) HIIT+ SAE, and (4) control. The tumor volume was significantly lower in the HIIT, SAE, and HIIT+SAE groups than in the controls. The protein level of caspase-3 in the HIIT and the SAE groups was higher than in the control and the HIIT+SAE groups. The Bax protein level in the SAE group was higher than in the control. The HIIT+SAE group showed a lower level of Bax than the HIIT and the SAE groups. The protein level of Bcl-2 was higher in the HIIT+SAE vs. both the HIIT and the SAE groups. Finally, the ratio of Bax/Bcl-2 was significantly higher in the HIIT and the SAE groups than in the HIIT+SAE and control groups. These findings indicate that a combination of HIIT and SAE interventions does not improve the apoptotic induction in tumor tissue, while both HIIT and SAE treatments may mediate apoptotic pathway as evinced by the elevated ratio of Bax/Bcl-2 and caspase-3 levels during tumor progression in breast cancer-bearing mice.

Restricted access